Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals, Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufac… Read more
Salarius Pharmaceuticals Inc (SLRX) - Net Assets
Latest net assets as of September 2025: $4.25 Million USD
Based on the latest financial reports, Salarius Pharmaceuticals Inc (SLRX) has net assets worth $4.25 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.10 Million) and total liabilities ($1.85 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.25 Million |
| % of Total Assets | 69.67% |
| Annual Growth Rate | N/A |
| 5-Year Change | -93.18% |
| 10-Year Change | -98.36% |
| Growth Volatility | 63.79 |
Salarius Pharmaceuticals Inc - Net Assets Trend (2014–2024)
This chart illustrates how Salarius Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Salarius Pharmaceuticals Inc (2014–2024)
The table below shows the annual net assets of Salarius Pharmaceuticals Inc from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.51 Million | -71.41% |
| 2023-12-31 | $5.29 Million | -49.09% |
| 2022-12-31 | $10.38 Million | -73.18% |
| 2021-12-31 | $38.72 Million | +74.75% |
| 2020-12-31 | $22.16 Million | +109.43% |
| 2019-12-31 | $10.58 Million | +13.99% |
| 2018-12-31 | $9.28 Million | -68.11% |
| 2017-12-31 | $29.11 Million | -50.93% |
| 2016-12-31 | $59.32 Million | -35.66% |
| 2015-12-31 | $92.19 Million | +1510.19% |
| 2014-12-31 | $-6.54 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Salarius Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7391275800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $144.00 | 0.01% |
| Other Components | $83.44 Million | 5519.31% |
| Total Equity | $1.51 Million | 100.00% |
Salarius Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Salarius Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scandinavian Real Heart AB (Publ)
F:7820
|
$4.77 Million |
|
TVA Group Inc
PINK:TVAGF
|
$4.77 Million |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
$4.78 Million |
|
Plaza Centers NV
WAR:PLZ
|
$4.78 Million |
|
Genesis Fertility Center Public Company Limited
BK:GFC
|
$4.77 Million |
|
Nam Song Hau Trading Investing Petroleum JSC
VN:PSH
|
$4.77 Million |
|
Interra Copper Corp
OTCQB:IMIMF
|
$4.77 Million |
|
MedNation AG
XETRA:EIF
|
$4.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Salarius Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,287,282 to 1,511,695, a change of -3,775,587 (-71.4%).
- Net loss of 5,575,777 reduced equity.
- New share issuances of 1,526,460 increased equity.
- Other factors increased equity by 273,730.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.58 Million | -368.84% |
| Share Issuances | $1.53 Million | +100.98% |
| Other Changes | $273.73K | +18.11% |
| Total Change | $- | -71.41% |
Book Value vs Market Value Analysis
This analysis compares Salarius Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.03x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $-278331.20 | $0.82 | x |
| 2015-12-31 | $61286.73 | $0.82 | x |
| 2016-12-31 | $54.54 | $0.82 | x |
| 2017-12-31 | $25.17 | $0.82 | x |
| 2018-12-31 | $7.69 | $0.82 | x |
| 2019-12-31 | $9663.06 | $0.82 | x |
| 2020-12-31 | $4246.01 | $0.82 | x |
| 2021-12-31 | $2794.36 | $0.82 | x |
| 2022-12-31 | $72.96 | $0.82 | x |
| 2023-12-31 | $24.17 | $0.82 | x |
| 2024-12-31 | $23.45 | $0.82 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Salarius Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -368.84%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.00x
- Recent ROE (-368.84%) is below the historical average (-135.89%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.36 Million |
| 2015 | -31.61% | 0.00% | 0.00x | 1.03x | $-38.36 Million |
| 2016 | -66.58% | -3906.33% | 0.02x | 1.07x | $-45.42 Million |
| 2017 | -118.31% | -2700.71% | 0.04x | 1.20x | $-37.34 Million |
| 2018 | -236.16% | -2615.99% | 0.08x | 1.12x | $-22.85 Million |
| 2019 | -65.55% | -200.18% | 0.25x | 1.31x | $-7.99 Million |
| 2020 | -33.18% | -140.49% | 0.21x | 1.13x | $-9.57 Million |
| 2021 | -32.97% | -693.84% | 0.05x | 1.05x | $-16.64 Million |
| 2022 | -304.37% | 0.00% | 0.00x | 1.41x | $-32.65 Million |
| 2023 | -237.22% | 0.00% | 0.00x | 1.25x | $-13.07 Million |
| 2024 | -368.84% | 0.00% | 0.00x | 2.00x | $-5.73 Million |
Industry Comparison
This section compares Salarius Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Salarius Pharmaceuticals Inc (SLRX) | $4.25 Million | 0.00% | 0.44x | $4.77 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |